MannKind Corp reports results for the quarter ended March 31 - Earnings Summary
08/05/2025 15:15
MannKind Corp MNKD.OQ reported quarterly adjusted earnings of 4 cents per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of five analysts for the quarter was for earnings of 4 cents per share. Wall Street expected results to range from 3 cents to 5 cents per share. Revenue rose 18.2% to $78.35 million from a year ago; analysts expected $76.13 million. MannKind Corp's reported EPS for the quarter was 4 cents. The company reported quarterly net income of $13.16 million. MannKind Corp shares had fallen by 3.6% this quarter and lost 24.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 46.7% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for MannKind Corp is $10.00 This summary was machine generated from LSEG data May 8 at 02:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | 0.04 | 0.04 | Met |
| Dec. 31 2024 | 0.04 | 0.03 | Missed |
| Sep. 30 2024 | 0.03 | 0.02 | Missed |
| Jun. 30 2024 | 0.01 | -0.01 | Missed |
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children